|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM298313596 |
| 003 |
DE-627 |
| 005 |
20240720232118.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.201902575
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1476.xml
|
| 035 |
|
|
|a (DE-627)NLM298313596
|
| 035 |
|
|
|a (NLM)31215123
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Liu, Ji
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 27.09.2019
|
| 500 |
|
|
|a Date Revised 20.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
|
| 520 |
|
|
|a A main challenge to broaden the biomedical application of CRISPR/Cas9 (clustered regularly interspaced short palindromic repeat (CRISPR) associated protein 9) genome editing technique is the delivery of Cas9 nuclease and single-guide RNA (sgRNA) into the specific cell and organ. An effective and very fast CRISPR/Cas9 genome editing in vitro and in vivo enabled by bioreducible lipid/Cas9 messenger RNA (mRNA) nanoparticle is reported. BAMEA-O16B, a lipid nanoparticle integrated with disulfide bonds, can efficiently deliver Cas9 mRNA and sgRNA into cells while releasing RNA in response to the reductive intracellular environment for genome editing as fast as 24 h post mRNA delivery. It is demonstrated that the simultaneous delivery of Cas9 mRNA and sgRNA using BAMEA-O16B knocks out green fluorescent protein (GFP) expression of human embryonic kidney cells with efficiency up to 90%. Moreover, the intravenous injection of BAMEA-O16B/Cas9 mRNA/sgRNA nanoparticle effectively accumulates in hepatocytes, and knocks down proprotein convertase subtilisin/kexin type 9 level in mouse serum down to 20% of nontreatment. The leading lipid nanoparticle, BAMEA-O16B, represents one of the most efficient CRISPR/Cas9 delivery nanocarriers reported so far, and it can broaden the therapeutic promise of mRNA and CRISPR/Cas9 technique further
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a CRISPR/Cas9
|
| 650 |
|
4 |
|a genome editing
|
| 650 |
|
4 |
|a lipid nanoparticles
|
| 650 |
|
4 |
|a messenger RNA delivery
|
| 650 |
|
7 |
|a Lipids
|2 NLM
|
| 650 |
|
7 |
|a RNA, Guide, CRISPR-Cas Systems
|2 NLM
|
| 650 |
|
7 |
|a RNA, Messenger
|2 NLM
|
| 650 |
|
7 |
|a Green Fluorescent Proteins
|2 NLM
|
| 650 |
|
7 |
|a 147336-22-9
|2 NLM
|
| 650 |
|
7 |
|a CRISPR-Associated Protein 9
|2 NLM
|
| 650 |
|
7 |
|a EC 3.1.-
|2 NLM
|
| 650 |
|
7 |
|a Proprotein Convertase 9
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.21.-
|2 NLM
|
| 700 |
1 |
|
|a Chang, Jin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jiang, Ying
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Meng, Xiandi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sun, Tianmeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mao, Lanqun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Qiaobing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Ming
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 31(2019), 33 vom: 17. Aug., Seite e1902575
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:31
|g year:2019
|g number:33
|g day:17
|g month:08
|g pages:e1902575
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.201902575
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 31
|j 2019
|e 33
|b 17
|c 08
|h e1902575
|